Aenitis Technologies is positioned as a world leader in bioproduction innovations through the use of acoustophoresis, the use of acoustic radiation forces aimed at the manipulation and preparation of cells in cell and gene therapies. The company is the result of the valorization of technologies developed by ESPCI Paris - PSL and the CNRS.
Aenitis develops bioproduction devices for cell and gene therapies with high added value, because they respond to the main challenges facing manufacturers, namely the ability to manipulate cells, without contact, without risk of contamination, and allowing them to work more in continuously with the aim of reducing production costs and in certain cases process times and increasing yields to make all these new biotherapies accessible.
Aenitis currently has a portfolio of 13 patent families.
The company is made up of 13 experienced employees with complementary expertise. Its 120 m² offices and laboratories are based at the St Louis hospital in Paris (center of excellence in hematology and cell therapy).
Original laboratory: PMMH Laboratory
Establishment: ESPCI Paris - PSL
Director: Emmanuel Vincent
